1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cutaneous T-Cell Lymphoma Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

SUMMARY
DelveInsight’s, “ Cutaneous T-Cell Lymphoma- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:
- A snapshot of the global Market therapeutics scenario for Cutaneous T-Cell Lymphoma.
- A review of the marketed products under prescription for Cutaneous T-Cell Lymphoma, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Cutaneous T-Cell Lymphoma with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Cutaneous T-Cell Lymphoma drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Cutaneous T-Cell Lymphoma drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Cutaneous T-Cell Lymphoma drugs.
- Coverage of Cutaneous T-Cell Lymphoma Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Cutaneous T-Cell Lymphoma key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Cutaneous T-Cell Lymphoma.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Cutaneous T-Cell Lymphoma.
- API intelligence over marketed drugs for Cutaneous T-Cell Lymphoma and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Cutaneous T-Cell Lymphoma.
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Cutaneous T-Cell Lymphoma Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
Table of Contents
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Route of Synthesis
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Phase III Drugs Information
- Phase III Drugs Description
- The United States Drug Master Filings (US DMF)
- Discontinued Drugs Information


List of Tables

Cutaneous T-Cell Lymphoma Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Cutaneous T-Cell Lymphoma Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Cutaneous T-Cell Lymphoma Therapeutic Market, US, (Year), 2014
Cutaneous T-Cell Lymphoma Marketed Drugs, API Manufacturers by US DMF Status, 2014
Cutaneous T-Cell Lymphoma Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Cutaneous T-Cell Lymphoma Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Cutaneous T-Cell Lymphoma Therapeutic Market, Global Sales (in million USD), 2014
Cutaneous T-Cell Lymphoma Marketed Drugs, API Manufacturers, Global, 2014
Cutaneous T-Cell Lymphoma Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Cutaneous T-Cell Lymphoma, 2014?


List of Figures

Cutaneous T-Cell Lymphoma Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Cutaneous T-Cell Lymphoma Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Cutaneous T-Cell Lymphoma Therapeutic Market, US, (Year), 2014
Cutaneous T-Cell Lymphoma Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Cutaneous T-Cell Lymphoma Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Cutaneous T-Cell Lymphoma Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Cutaneous T-Cell Lymphoma Therapeutic Market, Global Sales (in million USD), 2014
Cutaneous T-Cell Lymphoma Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market  Forecast-2023

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Small lymphocytic lymphoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in Russia

  • November 2016
    8 pages
  • Leukemia  

    Cancer  

    Radiography  

  • Russian Federat...  

View report >

Colorectal Cancer Statistics in the US - Forecast

  • November 2016
    14 pages
  • Colorectal Canc...  

  • United States  

View report >

Nursing Home Industry in Canada

  • November 2016
    13 pages
  • Nursing Home  

    Cancer  

  • Canada  

View report >

Related Market Segments :

Lymphoma

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.